Morning, Tuesday, 17th September 2019
THIS EVENT IS CPD CERTIFIED
This seminar will be an opportunity to discuss cancer care in England - looking at access to treatment, improving diagnosis and implementing new policy initiatives.
The seminar takes place in the context of the NHS Long Term Plan and the £400m additional funding for Cancer Alliances by 2023/24 to support ambitions within the Plan, including an increase in the diagnosis of cancer at stages 1 and 2 to three quarters of patients by 2028.
It comes as Rapid Diagnostic Centres are rolled out across England this year and a new faster diagnosis standard is set to be introduced from 2020. Planned sessions will consider priorities for implementing the new initiatives as well as supporting innovation in diagnosis.
Attendees will also discuss the next steps for improving cancer screening in England - following the publication of the interim report for the review of national cancer screening programmes in England, with the full report and recommendations due out later this year.
The agenda includes discussion on the future role of genomics in cancer care - looking at the progress of the Genomic Medicine Service, the personalisation of cancer treatment and overcoming challenges regarding patient data.
It follows the completion of the 100,000 Genomes Project in December 2018 and the announcement that the NHS will offer whole genome sequencing to every child and adult with certain cancers and rare diseases this year.
We also expect discussion on improving the quality of cancer care, as access to personalised care is due to be offered where appropriate to every person diagnosed with cancer by 2021. It follows the publication of the Universal Personalised Care: Implementing the Comprehensive Model, which sets out plans to embed personalised care in wider programmes including cancer care.
Following the Government’s announcement that the use of Artificial Intelligence and data to improve the diagnosis and treatment of chronic diseases will be included as one of the country’s Grand Challenge missions, this seminar will be an opportunity to consider early progress as well as identifying other opportunities to accelerate innovation in cancer treatment and for collaborative research.
Delegates will also discuss the development of the cancer care workforce - including improving access to specialists and priorities for education and training - as well as the progress of Health Education England’s Cancer Workforce Plan, which set out plans to increase the number of clinical endoscopists and reporting radiographers by 2021.
The expansion of multidisciplinary teams will also be considered - coming as primary care networks are due to help improve the early diagnosis of patients in their neighbourhoods by 2023/24.
We also expect discussion on the development of cancer drugs - looking at long-term investment, collaborative research and improving access to medicine.
Further sessions will look at the progress of the Cancer Drugs Fund, the impact of evidence compiled through data collection and the opportunities to increase managed access to innovative cancer treatments - including CAR T-cell therapy for adults with lymphoma, which was made accessible through the Cancer Drugs Fund earlier this year.